Ruslan Aleksandrovich Zukov
Krasnoyarsk State Medical University · 206 works · 2,464 citations · h-index 14
Top works
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry
- Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
- Current and Prospective Protein Biomarkers of Lung Cancer
- Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
- Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
- Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice
- Philosophical foundations of regional development of flagship universities
- Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5.
- Lipid Peroxidation and Antioxidant System in Erythrocytes of Patients with Renal Cell Carcinoma
- Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study
- DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma
- Role of maintaining therapy in the treatment of malignant neoplasms
- Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
- AEGEAN: A phase 3 trial of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
- The role of SAXS and molecular simulations in 3D structure elucidation of a DNA aptamer against lung cancer
- Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells
- Final Results of Phase II Trial (MIRACULUM) of the Novel PD-1 Inhibitor Prolgolimab in Patients with Advanced Melanoma